Which skin cancer is typically slow-growing and rarely metastasizes?

Study for the History and Physical (Handamp;P) Exam 1. Prepare with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Multiple Choice

Which skin cancer is typically slow-growing and rarely metastasizes?

Explanation:
Basal cell carcinoma tends to grow slowly and rarely metastasizes. It arises from the basal cells of the epidermis and, even though it can invade locally and cause tissue destruction if left untreated, it almost never spreads to lymph nodes or distant organs. This slow growth and low metastatic potential contrast with melanoma, which can grow quickly and spread early, squamous cell carcinoma which can metastasize in some cases, and Merkel cell carcinoma which is notably aggressive with a higher tendency to spread. Clinically, basal cell carcinoma often presents as a pearly, translucent papule with telangiectasias or an ulcerated lesion in sun-exposed areas, especially in older adults. Understanding this distinction helps prioritize urgency and management: the slow, local nature of basal cell carcinoma means excellent prognosis with appropriate local treatment.

Basal cell carcinoma tends to grow slowly and rarely metastasizes. It arises from the basal cells of the epidermis and, even though it can invade locally and cause tissue destruction if left untreated, it almost never spreads to lymph nodes or distant organs. This slow growth and low metastatic potential contrast with melanoma, which can grow quickly and spread early, squamous cell carcinoma which can metastasize in some cases, and Merkel cell carcinoma which is notably aggressive with a higher tendency to spread. Clinically, basal cell carcinoma often presents as a pearly, translucent papule with telangiectasias or an ulcerated lesion in sun-exposed areas, especially in older adults. Understanding this distinction helps prioritize urgency and management: the slow, local nature of basal cell carcinoma means excellent prognosis with appropriate local treatment.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy